Incyte's GAAP net income for 3 months of 2022 was $37.992 million, down 29% from $53.535 million in the previous year. Revenue rose 21.3% to $733.235 million from $604.718 million a year earlier.

Incyte's GAAP net income for 2021 was $948.581 million, compared to a loss of $295.697 million in the previous year. Revenue increased 12% to $2.986 billion from $2.667 billion a year earlier.

Incyte's GAAP net income for 9M 2021 amounted to $384.73 mln, against a loss of $445.547 mln in the previous year. Revenue increased 13.1% to $2.123 billion from $1.877 billion a year earlier.

Incyte has received FDA approval for its Opzelura cream. It is for the treatment of mild to moderate chronic atopic dermatitis in non-immunocompromised patients 12 years of age and older.